Viewing Study NCT05650918


Ignite Creation Date: 2025-12-25 @ 5:03 AM
Ignite Modification Date: 2026-02-21 @ 4:02 PM
Study NCT ID: NCT05650918
Status: COMPLETED
Last Update Posted: 2023-10-12
First Post: 2022-08-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)
Sponsor: Joachim Aerts, MD PhD
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Pancreatic Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Immunotherapy View
None CD40 agonist View
None Dendritic cell therapy View